The stock price of C4 Therapeutics Inc (NASDAQ: CCCC) has surged by 0.33 when compared to previous closing price of 6.70, but the company has seen a 4.38% gain in its stock price over the last five trading sessions. zacks.com reported 2024-08-01 that C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.73 per share a year ago.
Is It Worth Investing in C4 Therapeutics Inc (NASDAQ: CCCC) Right Now?
The 36-month beta value for CCCC is also noteworthy at 3.07. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CCCC is 58.28M, and at present, short sellers hold a 19.95% of that float. The average trading volume of CCCC on August 01, 2024 was 1.69M shares.
CCCC’s Market Performance
The stock of C4 Therapeutics Inc (CCCC) has seen a 4.38% increase in the past week, with a 48.72% rise in the past month, and a 2.78% gain in the past quarter. The volatility ratio for the week is 8.30%, and the volatility levels for the past 30 days are at 9.90% for CCCC. The simple moving average for the past 20 days is 13.60% for CCCC’s stock, with a 21.74% simple moving average for the past 200 days.
Analysts’ Opinion of CCCC
Many brokerage firms have already submitted their reports for CCCC stocks, with JP Morgan repeating the rating for CCCC by listing it as a “Neutral.” The predicted price for CCCC in the upcoming period, according to JP Morgan is $6 based on the research report published on January 29, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $12, previously predicting the price at $2. The rating they have provided for CCCC stocks is “Buy” according to the report published on December 13th, 2023.
Credit Suisse gave a rating of “Neutral” to CCCC, setting the target price at $10 in the report published on February 24th of the previous year.
CCCC Trading at 27.33% from the 50-Day Moving Average
After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.42% of loss for the given period.
Volatility was left at 9.90%, however, over the last 30 days, the volatility rate increased by 8.30%, as shares surge +48.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.10% upper at present.
During the last 5 trading sessions, CCCC rose by +4.80%, which changed the moving average for the period of 200-days by +239.17% in comparison to the 20-day moving average, which settled at $6.03. In addition, C4 Therapeutics Inc saw 18.97% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CCCC
Current profitability levels for the company are sitting at:
- -6.74 for the present operating margin
- 0.62 for the gross margin
The net margin for C4 Therapeutics Inc stands at -6.29. The total capital return value is set at -0.39. Equity return is now at value -48.42, with -31.74 for asset returns.
Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.32. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 68.23.
Currently, EBITDA for the company is -131.29 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 22.08. The receivables turnover for the company is 1.47for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.
Conclusion
In summary, C4 Therapeutics Inc (CCCC) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
